Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways

Geraniol attenuates 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced oxidative stress and inflammation in mouse skin: Possible role of p38 MAP Kinase and NF-κB

(2013) Abdul Quaiyoom Khan et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma

(2013) Paul G. Richardson et al.   LEUKEMIA RESEARCH

Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells

(2013) M R Milone et al.   Cell Death & Disease

HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway

(2013) X-F Qi et al.   Cell Death & Disease

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

(2012) R. Coleman et al.   ANNALS OF ONCOLOGY

Molecular pathogenesis of multiple myeloma and its premalignant precursor

(2012) W. Michael Kuehl et al.   JOURNAL OF CLINICAL INVESTIGATION

The 39th David A. Karnofsky Lecture: Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma

(2012) Kenneth C. Anderson   JOURNAL OF CLINICAL ONCOLOGY

Effects of Bone-Targeted Agents on Cancer Progression and Mortality

(2012) R. Coleman et al.   JNCI-Journal of the National Cancer Institute

Pathways of chemotherapy resistance in castration-resistant prostate cancer

(2011) K. L. Mahon et al.   ENDOCRINE-RELATED CANCER

Pharmacokinetic evaluation of zoledronic acid

(2011) Antonella De Luca et al.   Expert Opinion on Drug Metabolism & Toxicology

Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer

(2011) F. Dayyani et al.   JNCI-Journal of the National Cancer Institute

Breast-Cancer Adjuvant Therapy with Zoledronic Acid

(2011) Robert E. Coleman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells

(2011) Laura Bianchi et al.   PROTEOMICS

Biochemical and molecular mechanisms of action of bisphosphonates

(2010) Michael J. Rogers et al.   BONE

Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase

(2010) E Di Gennaro et al.   BRITISH JOURNAL OF CANCER

Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or Raltitrexed

(2010) Elena Di Gennaro et al.   CANCER BIOLOGY & THERAPY

A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer

(2010) Dana Rathkopf et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT

(2010) Francesca Bruzzese et al.   JOURNAL OF CELLULAR PHYSIOLOGY

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

(2010) Gareth J Morgan et al.   LANCET

Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis

(2009) F. Bruzzese et al.   MOLECULAR CANCER THERAPEUTICS

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

(2009) Michael Gnant et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combination Strategy Targeting the Hypoxia Inducible Factor-1  with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors

(2008) H. M.W. Verheul et al.   CLINICAL CANCER RESEARCH

Antitumor Effects of Doxorubicin Followed by Zoledronic Acid in a Mouse Model of Breast Cancer

(2008) P. D. Ottewell et al.   JNCI-Journal of the National Cancer Institute